Research Progress of ADAM17 in Gastric Cancer
10.12290/xhyxzz.2023-0383
- VernacularTitle:ADAM17在胃癌中的研究进展
- Author:
Mengjiao YANG
1
,
2
,
3
;
Hao YUAN
2
,
3
;
Ya ZHENG
2
,
3
;
Yuping WANG
2
,
3
;
Qinghong GUO
2
,
3
Author Information
1. Lanzhou University, First Clinical Medical College, Lanzhou 730000, China
2. Department of Gastroenterology, the First Hospital of Lanzhou University, Lanzhou 730000, China
3. Gansu Province Clinical Research Center for Digestive Diseases, Lanzhou 730000, China
- Publication Type:Review
- Keywords:
gastric cancer;
ADAM17;
mechanism of action;
targeted therapy;
prognosis
- From:
Medical Journal of Peking Union Medical College Hospital
2024;15(2):375-381
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is one of the most common malignant tumors in the world. Patients with gastric cancer are often treated by surgery, radiotherapy, chemotherapy or immunotherapy, but the clinical efficacy and prognosis are poor. As an important member of ADAMs family, a disintegrin and metalloprotease 17 (ADAM17) is significantly more highly expressed in gastric cancer than in adjacent tissues. It participates in the occurrence and development of gastric cancer by mediating EGFR, TNF-α, TGF-β/Smad, Notch and Wnt, FoxM1-ADAM17 and EGFR/ERK/SP1. The high expression of ADAM17 is also closely related to the poor prognosis of gastric cancer, suggesting that ADAM17 can be used as a biological index to predict the development and prognosis of gastric cancer and has great potential to become a new therapeutic target for gastric cancer. In this paper, the mechanism, treatment and prognosis of ADAM17 in the development of gastric cancer are reviewed, in order to provide new ideas for clinical diagnosis and treatment of gastric cancer.
